Document is current
Any future updates will be listed below
-
Authors
Rannou, François
Desallais, Lucille https://orcid.org/0009-0003-1514-6088
Nguyen, Christelle
Daste, Camille
Kirren, Quentin
Lefevre-Colau, Marie-Martine
Launay, Odile
Mouhsine, Hadley
Ruiz, Barbara
Moreau, Gabriel
Langenfeld, Florent https://orcid.org/0000-0002-3184-3401
Dolimier, Edita
Do, Hervé
Azoulai, René
Berenbaum, Francis https://orcid.org/0000-0001-8252-7815
Boissier, Marie-Christophe https://orcid.org/0000-0003-4199-8797
Salles, Jean-Pierre
Zagury, Jean-François https://orcid.org/0000-0003-4309-9277
- License Information
-
More Information
Article History
Received: 10 April 2025
Accepted: 21 September 2025
First Online: 5 November 2025
Competing interests
: F.R. has received honoraria or consulting fees from Grunenthal, FIDIA, and KIOmed as well as from Peptinov. F.R. served on the advisory Board for Peptinov. F.B. has received honoraria or consulting fees from Grunenthal, GSK, Eli Lilly, Novartis, Pfizer, Servier, 4 P Pharma, Viatris, Zoetis, and Peptinov. F.B. served on a Data Safety Monitoring Board or advisory Board for AstraZeneca, Sun Pharma, and Nordic Bioscience. F.B. is stockholder of 4 P Pharma and 4Moving Biotech. M.C.B. served on the advisory Board for Peptinov. L.D., H.M., B.R., G.M., F.L., E.D., H.D., R.A., and J.P.S. are employees of Peptinov company. J.F.Z., as the founder of Peptinov, owns stocks of the company. C.N., C.D., Q.K., M.M.L.C., and O.L. have no relevant affiliations or financial involvement with any organization with a financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
